Published in Immunity on January 01, 2005
Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer (2008) 9.82
Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol (2006) 7.76
Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res (2006) 3.52
Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go? Nat Clin Pract Oncol (2006) 2.97
Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR. J Immunol (2005) 2.83
Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J Immunol (2008) 2.54
Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood (2006) 2.11
T-cell receptor binding affinities and kinetics: impact on T-cell activity and specificity. Immunology (2009) 1.85
Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells. Clin Cancer Res (2009) 1.59
Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. J Clin Invest (2015) 1.41
A critical role of T cell antigen receptor-transduced MHC class I-restricted helper T cells in tumor protection. Proc Natl Acad Sci U S A (2005) 1.25
Enhanced immunogenicity of CTL antigens through mutation of the CD8 binding MHC class I invariant region. Eur J Immunol (2007) 1.24
Increasing functional avidity of TCR-redirected T cells by removing defined N-glycosylation sites in the TCR constant domain. J Exp Med (2009) 1.21
The impact of TCR-binding properties and antigen presentation format on T cell responsiveness. J Immunol (2009) 1.20
Efficient nonviral Sleeping Beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivity. Gene Ther (2009) 1.17
Relationship of p53 overexpression on cancers and recognition by anti-p53 T cell receptor-transduced T cells. Hum Gene Ther (2008) 1.17
Overcoming obstacles to the effective immunotherapy of human cancer. Proc Natl Acad Sci U S A (2008) 1.11
TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation. J Immunol (2008) 1.08
The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase. PLoS One (2009) 1.07
Intratumoral IL-12 gene therapy results in the crosspriming of Tc1 cells reactive against tumor-associated stromal antigens. Mol Ther (2010) 1.02
Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T Cells. Front Immunol (2013) 0.98
A T-cell receptor associated with naturally occurring human tumor immunity. Proc Natl Acad Sci U S A (2007) 0.96
Development of a genetically-modified novel T-cell receptor for adoptive cell transfer against renal cell carcinoma. J Immunol Methods (2011) 0.95
Distinct sets of alphabeta TCRs confer similar recognition of tumor antigen NY-ESO-1157-165 by interacting with its central Met/Trp residues. Proc Natl Acad Sci U S A (2008) 0.94
TCR gene transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 epitopes as melanoma-specific immune targets. Clin Dev Immunol (2012) 0.94
Generation of diffuse large B cell lymphoma-associated antigen-specific Vα6/Vβ13+T cells by TCR gene transfer. J Hematol Oncol (2011) 0.94
Functional differences between low- and high-affinity CD8(+) T cells in the tumor environment. Oncoimmunology (2012) 0.93
Molecular immunology lessons from therapeutic T-cell receptor gene transfer. Immunology (2010) 0.91
High-avidity autoreactive CD4+ T cells induce host CTL, overcome T(regs) and mediate tumor destruction. J Immunother (2009) 0.91
CD8 T cell tolerance to a tumor-associated self-antigen is reversed by CD4 T cells engineered to express the same T cell receptor. J Immunol (2014) 0.88
TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu. Front Immunol (2013) 0.87
Improving TCR Gene Therapy for Treatment of Haematological Malignancies. Adv Hematol (2012) 0.87
Transduction of an HLA-DP4-restricted NY-ESO-1-specific TCR into primary human CD4+ lymphocytes. J Immunother (2006) 0.87
Role of T cell receptor affinity in the efficacy and specificity of adoptive T cell therapies. Front Immunol (2013) 0.84
Characterization of MHC class-I restricted TCRalphabeta+ CD4- CD8- double negative T cells recognizing the gp100 antigen from a melanoma patient after gp100 vaccination. Cancer Immunol Immunother (2008) 0.83
TCR gene-modified T cells can efficiently treat established hepatitis C-associated hepatocellular carcinoma tumors. Cancer Immunol Immunother (2016) 0.80
Immunologic aspect of ovarian cancer and p53 as tumor antigen. J Transl Med (2005) 0.80
How (specific) would like your T-cells today? Generating T-cell therapeutic function through TCR-gene transfer. Front Immunol (2012) 0.79
Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognition. Cancer Immunol Immunother (2008) 0.79
Evaluating Human T-Cell Therapy of Cytomegalovirus Organ Disease in HLA-Transgenic Mice. PLoS Pathog (2015) 0.78
An optimized single chain TCR scaffold relying on the assembly with the native CD3-complex prevents residual mispairing with endogenous TCRs in human T-cells. Oncotarget (2016) 0.78
CD8 alpha is expressed by human monocytes and enhances Fc gamma R-dependent responses. BMC Immunol (2007) 0.78
Knockdown of T-bet expression in Mart-127-35 -specific T-cell-receptor-engineered human CD4(+) CD25(-) and CD8(+) T cells attenuates effector function. Immunology (2015) 0.76
Characterization of T-cell receptors directed against HLA-A*01-restricted and C*07-restricted epitopes of MAGE-A3 and MAGE-A12. J Immunother (2012) 0.75
Human leucocyte antigen class I-redirected anti-tumour CD4(+) T cells require a higher T cell receptor binding affinity for optimal activity than CD8(+) T cells. Clin Exp Immunol (2016) 0.75
The mutational status of p53 can influence its recognition by human T-cells. Oncoimmunology (2017) 0.75
The Pathway Tools software. Bioinformatics (2002) 14.89
TLR3 deficiency in patients with herpes simplex encephalitis. Science (2007) 5.86
Flexible nets. The roles of intrinsic disorder in protein interaction networks. FEBS J (2005) 5.36
Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med (2003) 4.90
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med (2010) 4.79
TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity (2004) 4.48
Exploiting the mutanome for tumor vaccination. Cancer Res (2012) 4.45
Cytarabine dose for acute myeloid leukemia. N Engl J Med (2011) 4.15
Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity (2011) 3.97
Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res (2004) 3.59
Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients. J Clin Invest (2011) 3.28
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother (2007) 3.16
Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest (2005) 3.11
CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest (2003) 2.97
Tumour immunity: effector response to tumour and role of the microenvironment. Lancet (2008) 2.94
Coupled folding and binding with alpha-helix-forming molecular recognition elements. Biochemistry (2005) 2.94
"MIATA"-minimal information about T cell assays. Immunity (2009) 2.90
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR. J Immunol (2005) 2.83
The unfoldomics decade: an update on intrinsically disordered proteins. BMC Genomics (2008) 2.72
Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood (2007) 2.61
Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. Blood (2005) 2.44
Cis association of Ly49A with MHC class I restricts natural killer cell inhibition. Nat Immunol (2004) 2.40
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res (2011) 2.26
The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A (2005) 2.22
Peripheral tolerance of CD8 T lymphocytes. Immunity (2005) 2.21
Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis Rheum (2008) 2.15
PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol (2009) 2.12
Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood (2006) 2.11
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer (2005) 2.08
Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood (2006) 2.00
The P4-type ATPase ATP11C is essential for B lymphopoiesis in adult bone marrow. Nat Immunol (2011) 1.96
Mining alpha-helix-forming molecular recognition features with cross species sequence alignments. Biochemistry (2007) 1.93
CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res (2010) 1.91
EDEM3, a soluble EDEM homolog, enhances glycoprotein endoplasmic reticulum-associated degradation and mannose trimming. J Biol Chem (2006) 1.91
Clinical outcomes of patients with severe aortic stenosis at increased surgical risk according to treatment modality. J Am Coll Cardiol (2011) 1.86
Harmonization of immune biomarker assays for clinical studies. Sci Transl Med (2011) 1.84
Human natural Treg microRNA signature: role of microRNA-31 and microRNA-21 in FOXP3 expression. Eur J Immunol (2009) 1.81
Ex vivo characterization of human CD8+ T subsets with distinct replicative history and partial effector functions. Blood (2003) 1.78
D²P²: database of disordered protein predictions. Nucleic Acids Res (2012) 1.75
New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. J Immunol (2006) 1.74
BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J Clin Invest (2009) 1.71
Clinical outcomes of patients with estimated low or intermediate surgical risk undergoing transcatheter aortic valve implantation. Eur Heart J (2013) 1.70
Melan-A/MART-1-specific CD8 T cells: from thymus to tumor. Trends Immunol (2002) 1.68
Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia. Blood (2012) 1.65
In vivo imaging of T cell delivery to tumors after adoptive transfer therapy. Proc Natl Acad Sci U S A (2007) 1.65
Follicular dendritic cells control engulfment of apoptotic bodies by secreting Mfge8. J Exp Med (2008) 1.65
Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium. Cancer Immunol Immunother (2009) 1.63
Cross-presenting human gammadelta T cells induce robust CD8+ alphabeta T cell responses. Proc Natl Acad Sci U S A (2009) 1.61
Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. Proc Natl Acad Sci U S A (2008) 1.59
Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunol Rev (2002) 1.58
A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML. Blood (2009) 1.58
Rational drug design via intrinsically disordered protein. Trends Biotechnol (2006) 1.57
Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia. Blood (2004) 1.55
Toll-like receptor 3 expressed by melanoma cells as a target for therapy? Clin Cancer Res (2007) 1.55
Criteria for defining a complete remission in acute myeloid leukaemia revisited. An analysis of patients treated in HOVON-SAKK co-operative group studies. Br J Haematol (2005) 1.54
In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses. J Clin Invest (2003) 1.54
Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor. Blood (2008) 1.51
MicroRNA-155 is required for effector CD8+ T cell responses to virus infection and cancer. Immunity (2013) 1.51
Improving protein order-disorder classification using charge-hydropathy plots. BMC Bioinformatics (2014) 1.50
RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood (2007) 1.47
Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. J Clin Oncol (2010) 1.46
Transcriptional profiling of Caulobacter crescentus during growth on complex and minimal media. J Bacteriol (2004) 1.46
Endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 prevents hypertensive cardiac remodeling in a blood pressure-independent manner. Hypertension (2011) 1.46
Control of organ transplant-associated graft-versus-host disease by activated host lymphocyte infusions. Transplantation (2004) 1.45
Thymic selection generates a large T cell pool recognizing a self-peptide in humans. J Exp Med (2002) 1.44
Uncoupling of proliferative potential and gain of effector function by CD8(+) T cells responding to self-antigens. J Exp Med (2002) 1.44
Impact of permanent pacemaker implantation on clinical outcome among patients undergoing transcatheter aortic valve implantation. J Am Coll Cardiol (2012) 1.44
Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity. Oncogene (2002) 1.42
Conservation of intrinsic disorder in protein domains and families: I. A database of conserved predicted disordered regions. J Proteome Res (2006) 1.42
Reduced expression of Hugl-1, the human homologue of Drosophila tumour suppressor gene lgl, contributes to progression of colorectal cancer. Oncogene (2005) 1.41
Abdominal obesity, insulin resistance, and metabolic syndrome in a southern European population. Eur J Intern Med (2003) 1.41
A methodological framework to enhance the clinical success of cancer immunotherapy. Nat Biotechnol (2011) 1.38
Tumor-specific CD4+ T cells render the tumor environment permissive for infiltration by low-avidity CD8+ T cells. J Immunol (2008) 1.38
Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res (2010) 1.38
Heat shock cognate protein 70 is involved in rotavirus cell entry. J Virol (2002) 1.37
Rotavirus gene silencing by small interfering RNAs. EMBO Rep (2002) 1.36
Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. J Clin Invest (2002) 1.36
A constant affinity threshold for T cell tolerance. J Exp Med (2007) 1.36
A spontaneously arising pancreatic tumor does not promote the differentiation of naive CD8+ T lymphocytes into effector CTL. J Immunol (2004) 1.34
Predictors of functional decline in elderly patients undergoing transcatheter aortic valve implantation (TAVI). Eur Heart J (2012) 1.33
Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. J Immunol (2010) 1.33
Immuno-monitoring of CD8+ T cells in whole blood versus PBMC samples. J Immunol Methods (2005) 1.33
Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML). Blood (2004) 1.33
The cooperative induction of hypoxia-inducible factor-1 alpha and STAT3 during hypoxia induced an impairment of tumor susceptibility to CTL-mediated cell lysis. J Immunol (2009) 1.32
Toll-like receptors' two-edged sword: when immunity meets apoptosis. Eur J Immunol (2007) 1.32
Hypoxia-inducible miR-210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells. Cancer Res (2012) 1.30
Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA. Cancer Immun (2004) 1.29
Human effector CD8+ T lymphocytes express TLR3 as a functional coreceptor. J Immunol (2006) 1.28